| Product NDC: | 0004-6313 | 
| Proprietary Name: | Naprosyn | 
| Non Proprietary Name: | naproxen | 
| Active Ingredient(s): | 250 mg/1 & nbsp; naproxen | 
| Administration Route(s): | ORAL | 
| Dosage Form(s): | TABLET | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 0004-6313 | 
| Labeler Name: | Genentech, Inc. | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | NDA017581 | 
| Marketing Category: | NDA | 
| Start Marketing Date: | 19760311 | 
| Package NDC: | 0004-6313-01 | 
| Package Description: | 100 TABLET in 1 BOTTLE, PLASTIC (0004-6313-01) | 
| NDC Code | 0004-6313-01 | 
| Proprietary Name | Naprosyn | 
| Package Description | 100 TABLET in 1 BOTTLE, PLASTIC (0004-6313-01) | 
| Product NDC | 0004-6313 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | naproxen | 
| Dosage Form Name | TABLET | 
| Route Name | ORAL | 
| Start Marketing Date | 19760311 | 
| Marketing Category Name | NDA | 
| Labeler Name | Genentech, Inc. | 
| Substance Name | NAPROXEN | 
| Strength Number | 250 | 
| Strength Unit | mg/1 | 
| Pharmaceutical Classes | Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |